Jilin Aodong Pharmaceutical Group Co Ltd

Jilin Aodong Pharmaceutical Group Co Ltd maintains a strong capital structure with a low debt-to-equity ratio of 0.08, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.74, suggesting it can cover its short-term obligations but with limited surplus. However, the company reported negative operating cash flow of -20.37 million CNY and capital expenditures of -186.76 million CNY, which may signal ongoing investment in operations or asset maintenance.

In terms of profitability, the company's return on equity (ROE) is 1.39%, and its return on assets (ROA) is 1.18%. These figures are below the typical thresholds for high-performing pharmaceutical firms, indicating that the company is generating relatively modest returns on its equity and asset base. The gross profit margin is 35.14% (193.41 million CNY on 550.40 million CNY revenue), which is in line with industry norms, but the operating margin of 63.44% (349.17 million CNY on 550.40 million CNY revenue) is strong, suggesting efficient cost management.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification beyond China. This concentration increases exposure to domestic regulatory and economic risks, as well as potential shifts in healthcare policy or demand.

Looking ahead, the company's growth trajectory is uncertain. While it reported revenue of 550.40 million CNY in the latest period, there is no disclosed revenue growth rate or outlook for the next fiscal year. The absence of a clear growth narrative or expansion plans in the available data suggests the company may be in a stable but not rapidly growing phase.

The company's risk profile includes medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. However, the company's negative operating cash flow and capital expenditures may require future financing, which could introduce dilution pressure if not offset by internal cash generation.

Recent events and disclosures do not include material changes in strategy, new product launches, or significant regulatory actions. The company's ESG score of 34.66 and a governance score of 74.10 suggest moderate environmental and social performance but relatively strong governance practices. The ESG controversies score of 100 indicates no major controversies, which is a positive signal for long-term stability.

Jilin Aodong Pharmaceutical Group Co Ltd (000623.SZ) has undergone a significant update to its corporate taxonomy, with its primary activity now explicitly classified as "Pharmaceuticals" and its economic sector identified as "Healthcare" [doc:000623.sz-ha-financials]. This formalization of the company’s sectoral identity provides a clearer framework for understanding its operational focus within the broader healthcare industry. Concurrently, the company’s risk profile has been refined with the introduction of specific risk assessments. Dilution risk is now categorized as "low," suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances [doc:000623.sz-ha-esg]. This assessment offers investors a baseline for evaluating the security of their equity position. In contrast, liquidity risk has been assessed as "medium," indicating potential variability in the company’s ability to meet short-term obligations or trade volume constraints [doc:000623.sz-ha-esg]. This distinction between low dilution and medium liquidity risk highlights a nuanced financial landscape where capital stability coexists with potential market or cash flow fluidity challenges. These updates collectively enhance the transparency of Jilin Aodong’s financial and operational metrics. By clarifying its sector classification and defining key risk parameters, the company provides a more structured basis for stakeholder analysis, although no changes were detected in analyst coverage, index membership, or top holder counts.

Net income surged 64.1% year-over-year to CNY 2.4 billion, demonstrating strong profitability growth despite revenue declines.

Free cash flow increased 109.2% year-over-year to CNY 1.8 billion, highlighting robust cash generation capabilities.

Debt-to-equity ratio of 0.08 is below the cohort median of 0.18, suggesting a conservative leverage profile.

The company faces high credit risk, which could impair financial stability and increase borrowing costs significantly.

Cash conversion ratio of -0.05 ranks in the bottom quartile, suggesting poor translation of earnings into cash.

Revenue CAGR of -2.7% over four years indicates a persistent long-term decline in sales volume.

Revenue ¥2.61B, −24,3% YoY; Operating income +8,4% YoY.

• ▍Revenue ¥2.61B, −24,3% YoY
• ▍Operating income +8,4% YoY
• ▍Net income +6,3% YoY
• ▍Free cash flow −50,9% YoY
• ▍Net margin 59.4%